Madrigal (MDGL) Form 144: RSU-Vested Shares Proposed for Sale via Morgan Stanley
Rhea-AI Filing Summary
Madrigal Pharmaceuticals, Inc. (MDGL) Form 144 notice reports a proposed sale of securities by a person for whose account shares vested as restricted stock units. The filer plans to sell two lots of Common Stock through Morgan Stanley Smith Barney LLC on 08/18/2025: 458 shares (aggregate market value $169,386.72) and 846 shares (aggregate market value $312,884.64). Both lots were acquired on 08/15/2025 by vesting of restricted stock units from the issuer. The filing states there were no sales by the filer in the prior three months and includes the required attestation about material nonpublic information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insiders propose a small, post-vesting sale of 1,304 shares executed via a broker on a single date.
The document discloses a proposed sale of 1,304 total shares acquired by RSU vesting on 08/15/2025, to be sold on 08/18/2025 through Morgan Stanley Smith Barney LLC. The filing reports aggregate market values for the two lots as provided and confirms no sales in the prior three months. Based solely on the filing, this is a routine notice required under Rule 144 documenting the insider's intention to sell shares that vested from an equity grant.
TL;DR: Form 144 documents a standard, disclosed insider sale following RSU vesting, with required signature attestations.
The notice identifies the securities as common stock acquired via restricted stock unit grants from the issuer on 08/15/2025. The filer represents they are unaware of undisclosed material adverse information, and no sales were reported in the prior three months. The filing lists the executing broker and planned sale date, meeting procedural disclosure requirements under Rule 144.